Area of Interest:

Pharmacology and Toxicology

100%

Preclinical Pharmacology

62%

Biopharmaceuticals

90%

Immunohistochemistry

75%

Flow Cytometry

55%

Research Publications in Numbers

Books
0

Chapters
0

Articles
0

Abstracts
0

Shi, Q.J., H. Wang, Z.X. Liu, S.H. Fang and X.M. Song et al., 2015. HAMI 3379, A Cyslt2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience, 291: 53-69.
CrossRef | PubMed |
Zhao, B., M. Zhang, X. Han, X.Y. Zhang and Q. Xing et al., 2013. Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism. PLoS One, 8: e85403-e85403.
CrossRef | Direct Link |
Zhang, X.Y., X.R. Wang, D.M. Xu, S.Y. Yu and Q.J. Shi et al., 2013. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J. Pharmacol. Exp. Ther., 346: 328-341.
CrossRef | PubMed |
Shi, W.Z., C.Z. Zhao, B. Zhao, Q.J. Shi and L.H. Zhang et al., 2012. Aggravated inflammation and increased expression of cysteinyl leukotriene receptors in the brain after focal cerebral ischemia in AQP4-deficient mice. Neurosci. Bull., 28: 680-692.
CrossRef | PubMed |
Shi, Q.J., L. Xiao, B. Zhao, X.Y. Zhang and X.R. Wang et al., 2012. Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Res., 1484: 57-67.
CrossRef |